Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has appointed Michael “Zappy” Zapolin as chief executive officer. The leadership change places Zapolin at the helm of a company preparing for a public listing and a nationwide commercial launch in the United States, according to the announcement disseminated on behalf of Quantum BioPharma Ltd..
Zapolin’s mandate includes securing financing and listing Unbuzzd on a stock exchange, followed by a full-scale marketing and product rollout across the U.S. market. Former CEO Richard Buzbuzian is assisting with the transition to a publicly listed company, which is scheduled to go effective in the next quarter. The move signals a significant step for Unbuzzd as it seeks to capitalize on growing consumer interest in functional beverages and wellness products.
Unbuzzd markets unbuzzd™, a beverage designed to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms. The company said the product is backed by a peer-reviewed clinical study and is currently available through Amazon and its website. The appointment of a CEO with a track record in launching and scaling consumer brands could help Unbuzzd capture a larger share of the rapidly expanding hangover-remedy and functional beverage market.
For Quantum BioPharma, the development carries direct financial implications. Quantum invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% of Unbuzzd as of March 31, 2026. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once that threshold is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. A successful public listing and nationwide rollout by Unbuzzd could therefore generate substantial royalty income for Quantum, strengthening its balance sheet and supporting its broader biopharmaceutical research.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The potential royalty stream from Unbuzzd could provide non-dilutive funding to advance these clinical programs.
Investors seeking the full press release can visit https://ibn.fm/CBNq1. The latest news and updates relating to QNTM are available in the company’s newsroom, and the announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication and social media distribution to millions of followers, along with corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
